Screening & Surveillance Guidelines
|
|
- Rosalyn Lewis
- 5 years ago
- Views:
Transcription
1 Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following five criteria*: 1. Patient of a participating clinic: This is determined by administrators and medical staff of the participating clinics, using their usual, internal definition of clinic patient 2. Income at or below 250% of the Federal Poverty Level: This is determined by participating clinics based on the information in Figure Need for colorectal screening: This is determined by participating clinics based on adherence to screening guidelines issued by the American Cancer Society (Figure 2-2) Persons who have had a colonoscopy in the past 10 years (without adenomas being detected) are not eligible Persons who have had a sigmoidoscopy or a barium enema in the past 5 years are not eligible for a sigmoidoscopy or barium enema, but they are eligible for a colonoscopy A positive or negative fecal occult blood test (FOBT) test, regardless of how recent the test was, does not affect eligibility for a sigmoidoscopy or colonoscopy through the Program The Colorectal Screening Referral Form (Figure 2-3) must be completed and signed by the patient s primary care provider prior to screening and a copy must remain in the chart 4. Have no health insurance or have an insurance plan that does not cover any cost for endoscopic colorectal screening: This criteria is to be determined by each clinic, based on patient reports. Patients who have insurance plans that cover any of the cost for endoscopic colorectal screening are not eligible for the Program, regardless of the cost of the co-pay or deductible of the plan. Patients covered by insurance plans which do not cover any costs for endoscopic colorectal screening, as well those who are uninsured, are eligible for the Program 5. Must be lawfully present in the United States: See Chapter 3 for requirements of lawful presence *Participating clinics are responsible for documenting eligibility information including lack of coverage of endoscopic colorectal screening, and will be asked to present this information at the time of chart audit by the Program Clinic Enrollment Protocol Clinics and Hospitals enrolled in the Colorado Colorectal Screening Program shall provide primary care services to patients who are referred to the Program for endoscopic colorectal screening. The majority of clinics and hospitals enrolled can be referred to as the safety net for primary care and include members of the Colorado Community Health Network (CCHN), Colorado Rural Health Center (CRHC), and Clinic Net (CN). Rev
2 Clinics and Hospitals not under the umbrella of CCHN, CRHC, or CN who wish to enroll as a Program partner will be considered on a case-by-case basis. Inclusion criteria may be based on one or more of the following conditions: 1. Clinics and Hospitals must provide primary care to clients who are eligible and referred to the Program 2. Clinics and Hospitals provide care to the medically underserved in geographical regions and communities where a CCHN, CRHC or CN system is not currently established 3. Clinic and Hospitals are serving special populations who are in need of medical care but do not have access to or are not permitted to be a client of CCHN, CRHC, or CN 4. Clinic and Hospital systems who provide endoscopic screening services within their system, agree to partner with other participating health clinics to provide screening when capacity is available and the need is identified The Program Director will make the final decision about Clinic or Hospital inclusion into the Program. Figure 2-1: 250% of Federal Poverty Guidelines The Colorado Colorectal Screening Program uses poverty guidelines to determine eligibility based on number of persons in the family unit. The Program allows for an income at or below 250% of the Federal Poverty Level (FPL). The poverty level is established by the Department of Health and Human Services, 250% is 2.5 times the amount of the poverty level. The Program will allow inclusion of patients who have no income to those who have an income up to 250% of the FPL. Table 2-1 should be used as a guide to understand income levels. Clinics should use existing methodologies for verification of patient income to establish income level. Poverty guidelines are updated annually by the federal government, and are usually released by mid February of that year. You can find the current poverty guidelines with calculated percentages at Rev
3 II. Screening Methods This Program supports informed decision making in screening, a process that each patient with his/her provider needs to complete. The Program will reimburse near the Medicare Allowable Reimbursement Rate for associated screening services in the age and risk eligible populations. All rates will be negotiated on an individual basis. Screening Methods Covered The endoscopic screening sections of the American Cancer Society guidelines (Figure 2-2) serve to guide the Program. These are the same endoscopic screening guidelines currently endorsed by the Colorado Clinical Guidelines Collaborative. Flexible Sigmoidoscopy is a direct visualization of the inside of the lower half of the colorectum, often to the point of the splenic flexure, through a flexible sigmoidoscope. This procedure is reimbursed by the Program. Biopsy during flexible sigmoidoscopy should be performed for any polyp smaller than 1 cm since hyperplastic polyps seen by flexible sigmoidoscopy are not an indication for full colonoscopy. Patients with histologically proven adenoma or with polyps greater than 1 cm in size (which are nearly always adenomas) should be referred for colonoscopy. Colonoscopy is the direct examination of the entire length of the colon via a colonoscope. All costs associated with a colonoscopy (provider, facility, anesthesia and pathology) are reimbursed by the Program. Colonoscopy is a screening test, but it is often also a diagnostic test and/or a treatment procedure when lesions are identified, biopsied and/or removed. The goal during a colonoscopy is that all lesions identified as cancer or polyps (sessile or pedunculated) be excised or, if too large for excision, biopsied, and sent for pathologic examination. An exception is when numerous (over 10-20) small (< 5mm) polyps are encountered in the rectum and distal colon; since these are typically hyperplastic polyps, representative biopsies of 5-10 can be obtained. Pathologic evaluation of colonic polyps is critical to determine the individual s risk category for CRC, the first degree relatives risk of CRC, and the proper interval for repeat CRC testing. An adequate colonoscopy is one that reaches the cecum and visualized over 90% of the colonic mucosal surface. Double Contrast Barium Enema (DCBE) is less sensitive than colonoscopy for colorectal neoplasms. Therefore, it is rarely elected as a primary screening method, though it can be reimbursed by the Program. Its use should be reserved for situations in which a patient and provider determine that a screening DCBE is the best screening option. Rev
4 Support for Systems Change The Program is able to provide support for clinics to implement sustainable systems for comprehensive cancer screening to include the following screening methods: High Sensitivity Fecal Occult Blood Tests (FOBT) High Sensitivity Fecal immunochemical tests (FIT) The Program offers training on implementing systems changes to increase colorectal cancer screening rates in your practice. These include a written office policy, an office reminder system and a high quality stool blood screening test in addition to endoscopy screening. Additionally, the Program is partnering with community health centers and local public health to implement Flu-FOBT clinics during annual flu seasons. The Program is able to offer no cost colonoscopies for patients with a positive FOBT/FIT who meet eligibility guidelines. Screening Methods NOT Covered Stool DNA test (sdna) CT Colonography (Virtual Colonoscopy) Digital Rectal Exam (DRE) should be performed at the time of colonoscopy or sigmoidoscopy. This test is NOT reimbursed separately by the Program. Rev
5 Figure 2-2: ACS Colorectal Screening Guidelines (03/2008) Beginning at age 50, both men and women at average risk for developing colorectal cancer should use one of the screening tests below. The tests that are designed to find both early cancer and polyps are preferred if these tests are available and an individual is willing to have one of these more invasive tests. Tests that find polyps and cancer Flexible sigmoidoscopy every 5 years* Colonoscopy every 10 years Double contrast barium enema every 5 years* CT colonography (virtual colonoscopy) every 5 years* Tests that mainly find cancer High sensitivity fecal occult blood test (FOBT) every year*,** Fecal immunochemical test (FIT) every year*,** *Colonoscopy should be done if test results are positive **For FOBT or FIT used as a screening test, the take-home multiple sample method should be used. A FOBT or FIT done during a digital rectal exam in the doctor's office is not adequate for screening People should talk to their doctor about starting colorectal cancer screening earlier and/or being screened more often if they have any of the following colorectal cancer risk factors: A personal history of colorectal cancer or adenomatous polyps A personal history of chronic inflammatory bowel disease (Crohn s disease or ulcerative colitis) A strong family history of colorectal cancer or polyps (cancer or polyps in a firstdegree relative [parent, sibling, or child] younger than 60 or in 2 or more first-degree relatives of any age) A known family history of hereditary colorectal cancer syndromes such as familial adenomatous polyposis (FAP) or hereditary non-polyposis colon cancer (HNPCC) Rev
6 Figure 2-3: PCP Referral Form Rev
7 III. Screening & Surveillance Guidelines Figure 2-4: Reimbursable Screening Guidelines for Average, Increased, and High Risk Patients (10/2006) Risk Category Age to Begin Reimbursable Screening Recommendation Average Risk Asymptomatic individuals who are not in the categories below (including those with a previous hyperplastic polyp as their most advanced lesion) 50 years Age to stop screening: 85 Note: Cormorbidity should be considered for those between Colonoscopy every 10 years OR Flexible Sigmoidoscopy or DCBE every 5 years Increased Risk Individual age 45 and older with blood in the stool or a positive FOBT are eligible for endoscopic evaluation through CCSP Either colorectal cancer or adenomatous polyps, in any first-degree relative before age 60, or in two or more first-degree relatives at any age (if not a hereditary syndrome) On previous endoscopic screening, individual with one or two small (<1 cm), adenomatous polyps with only low-grade dysplasia and/or sessile serrated polyp without dysplasia On previous endoscopic screening, individual with any of the following: - 3 to 10 adenomas or - one large ( 1 cm) adenomatous polyp or - any sessile serrated polyp with cytologic dysplasia On previous endoscopic screening, individual with more than 10 adenomas at one examination Personal history of curative-intent resection of colorectal cancer 45 with symptoms Colonoscopy Age 40 or 10 years before the youngest colon cancer / adenoma in the family, whichever is earlier At initial time of polyp diagnosis At initial time of polyp diagnosis At initial time of polyp diagnosis One year after diagnosis Colonoscopy every 5-10 years Colorectal cancer in relatives more distant than first-degree does not increase risk substantially above the average-risk group Colonoscopy 5 years after initial polyp removal. If that exam is normal, then colonoscopy every 5 10 years thereafter. Colonoscopy 3 years (providing that piecemeal removal has not been done & the adenoma(s) are completely removed) If the follow-up exam is normal or shows only one or two small tubular adenomas with lowgrade dysplasia, then colonoscopy every 5 years thereafter. < 3 years interval established by clinical judgment Colonoscopy one year after resection. If normal, then the interval before next subsequent exam should be 3 years. If normal, then the interval before next subsequent exam should be 5 years. High Risk Individual with family history of Familial Adenomatous Polyposis (FAP) Individual with family history of hereditary nonpolyposis colon cancer (HNPCC) Puberty Age 21 to 25 years Sigmoidoscopy (or colonoscopy) and genetic testing. If polyposis is confirmed by endoscopy and/or if genetic testing is positive, then refer patient to a center with experience in managing FAP. Colonoscopy and genetic testing*. If genetic test is normal, screen as per average risk. Rev
8 Personal history of inflammatory bowel disease: (Chronic Ulcerative colitis or Crohn s disease) Cancer risk begins to be significant 8 years after the onset of pancolitis OR years after the onset of left sided colitis If genetic test is positive or patient has not had genetic testing, then refer patient to a center with experience in managing HNPCC. Colonoscopy with multiple biopsies every 1 2 years, and refer patient to a center with experience in surveillance and management of IBD Important Note: The Program can only cover the costs of colorectal cancer screening in patients with established, long standing disease (>8 years) and not for the diagnosis or symptomatic evaluation of patients with IBD. Patients with signs or symptoms of colorectal cancer need to be managed individually with a diagnostic work up. In some cases, endoscopic evaluation of patients with signs and symptoms can be reimbursed through this Program. In addition, patients with hematochezia or a positive FOBT between ages will be considered eligible for endoscopic evaluation under this Program. Genetic testing may be recommended but is not a reimbursable item through the Program. Guidelines for Colonoscopy Surveillance after Polypectomy: A Consensus Update by the U.S. Multi-Society Task Force on Colorectal Cancer and the American Cancer Society Full Article - CA Cancer J Clin 2006;56: A. Surveillance Recommendations 1. Patients with small rectal hyperplastic polyps should be considered to have normal colonoscopies, and therefore the interval before subsequent colonoscopy should be 10 years. An exception is patients with a hyperplastic polyposis syndrome. They are at increased risk for adenomas and colorectal cancer and need to be identified for more intensive follow up. 2. Patients with only one or two small (< 1 cm) tubular adenomas with only low-grade dysplasia should have their next follow-up colonoscopy in 5 to 10 years. The precise timing within this interval should be based on other clinical factors (such as prior colonoscopy findings, family history, and the preferences of the patient and judgment of the physician). 3. Patients with 3 to 10 adenomas, or any adenoma > 1 cm, or any adenoma with villous features, or high-grade dysplasia should have their next follow-up colonoscopy in 3 years providing that piecemeal removal has not been done and the adenoma(s) are completely removed. If the follow-up colonoscopy is normal or shows only one or two small tubular adenomas with low-grade dysplasia, then the interval for the subsequent examination should be 5 years. 4. Patients who have more than 10 adenomas at one examination should be examined at a shorter (< 3 years) interval established by clinical judgment, and the clinician should consider the possibility of an underlying familial syndrome. Rev
9 5. Patients with sessile adenomas that are removed piecemeal should be considered for follow up at short intervals (2 to 6 months) to verify complete removal. Once complete removal has been established, subsequent surveillance needs to be individualized based on the endoscopist s judgment. Completeness of removal should be based on both endoscopic and pathologic assessments. 6. More intensive surveillance is indicated when the family history is suggestive of any of the familial colon cancer syndromes. B. Additional Surveillance Considerations 1. The present recommendations assume that colonoscopy is complete to the cecum and that bowel preparation is adequate. A repeat examination should be done if the bowel preparation is not adequate before planning a long-term surveillance program. 2. There is clear evidence that the quality of examination is highly variable. A continuous quality improvement process is critical to the effective application of colonoscopy in colorectal cancer prevention. 3. A repeat examination is warranted if there is a concern that the polyp is incompletely removed, particularly if it shows high-grade dysplasia. 4. Endoscopists should make clear recommendations to primary care providers about when the next colonoscopy is indicated. 5. Given the evolving nature of guidelines, it is important that physicians and patients should remain in contact so that surveillance recommendations reflect changes in guidelines. 6. Pending further investigation, performance of fecal occult blood test is discouraged in patients undergoing colonoscopic surveillance. 7. Discontinuation of surveillance colonoscopy should be considered in persons with serious comorbidities with less than 10 years of life expectancy, according to the clinician s judgment. 8. The application of evolving technologies such as chromoendoscopy, magnification endoscopy, narrow-band imaging, and computed tomography colonography are not established for postpolypectomy surveillance at this time. Guidelines for Colonoscopy Surveillance after Cancer Resection: A consensus Updated by the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer Full Article - CA Cancer J Clin 2006: A. Post-Cancer Resection Surveillance Colonoscopy Recommendations 1. Patients with colon and rectal cancer should undergo high quality perioperative clearing. In the case of nonobstructing tumors, this can be done by preoperative colonoscopy. In the case of obstructing colon cancers, computed tomography colonography with intravenous contrast or double contrast barium enema can be used to detect neoplasms in the proximal colon. In these cases, a colonoscopy to clear the Rev
10 colon of synchronous disease should be considered 3 to 6 months after the resection if no unresectable metastases are found during surgery. Alternatively, colonoscopy can be performed intraoperatively. 2. Patients undergoing curative resection for colon or rectal cancer should undergo a colonoscopy 1 year after the resection (or 1 year following the performance of the colonoscopy that was performed to clear the colon of synchronous disease). This colonoscopy at 1 year is in addition to the perioperative colonoscopy for synchronous tumors. 3. If the examination performed at 1 year is normal, then the interval before the next subsequent examination should be 3 years. If that colonoscopy is normal, then the interval before the next subsequent examination should be 5 years. 4. Following the examination at 1 year, the intervals before subsequent examinations may be shortened if there is evidence of hereditary nonpolyposis colorectal cancer or if adenoma findings warrant earlier colonoscopy. 5. Periodic examination of the rectum for the purpose of identifying local recurrence, usually performed at 3 to 6 month intervals for the first 2 or 3 years, may be considered after low anterior resection of rectal cancer. The techniques utilized are typically rigid proctoscopy, flexible proctoscopy, or rectal ultrasound. These examinations are independent of the colonoscopic examinations described above for detection of metachronous disease. B. Additional Recommendations Regarding Post-Cancer Resection Surveillance Colonoscopy 1. These recommendations assume that colonoscopy is complete to the cecum and that bowel preparation is adequate. 2. There is clear evidence that the quality of examinations is highly variable. A continuous quality improvement process is critical to the effective application of colonoscopy in colorectal cancer prevention. 3. Endoscopists should make clear recommendations to primary care physicians about when the next colonoscopy is indicated. 4. Performance of fecal occult blood test is discouraged in patients undergoing colonoscopic surveillance. 5. Discontinuation of surveillance colonoscopy should be considered in persons with advanced age or comorbidities (with less than 10 years of life expectancy), according to the clinician s judgment. 6. Surveillance guidelines are intended for asymptomatic people. New symptoms may need diagnostic workup. 7. Chromoendoscopy (dye-spraying) and magnification endoscopy are potentially helpful but not established as essential to screening or surveillance. Rev
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationRazvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER
Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER Epidemiology of CRC Colorectal cancer (CRC) is a common and lethal disease Environmental
More informationEARLY DETECTION OF COLORECTAL CANCER. Epidemiology of CRC
Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER Epidemiology of CRC Colorectal cancer (CRC) is a common and lethal disease Environmental
More informationCLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING
CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING This guideline is designed to assist practitioners by providing the framework for colorectal cancer (CRC) screening, and is not intended to replace
More informationColon Cancer Screening & Surveillance. Amit Patel, MD PGY-4 GI Fellow
Colon Cancer Screening & Surveillance Amit Patel, MD PGY-4 GI Fellow Epidemiology CRC incidence and mortality rates vary markedly around the world. Globally, CRC is the third most commonly diagnosed cancer
More informationStructured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007
Structured Follow-Up after Colorectal Cancer Resection: Overrated R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Guidelines for Colonoscopy Production: Surveillance US Multi-Society
More informationColon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4
Colon Cancer Screening Layth Al-Jashaami, MD GI Fellow, PGY 4 -Colorectal cancer (CRC) is a common and lethal cancer. -It has the highest incidence among GI cancers in the US, estimated to be newly diagnosed
More informationDIGESTIVE SYSTEM SURGICAL PROCEDURES May 1, 2015 INTESTINES (EXCEPT RECTUM) Asst Surg Anae
ENDOSCOPY Z50 Duodenoscopy (not to be claimed if Z399 and/or Z00 performed on same patient within 3 months)... 92.10 Z9 Subsequent procedure (within three months following previous endoscopic procedure)...
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationHistorical. Note: The parenthetical numbers in the Clinical Indications section refer to the source documents cited in the References Section below.
Clinical UM Guideline Subject: Colonoscopy Guideline #: CG-SURG-01 Current Effective Date: 01/21/2015 Status: Revised Last Review Date: 05/15/2014 Description Colonoscopy describes the direct visual inspection
More informationColon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership
Colon Screening in 2014 Offering Patients a Choice Clark A Harrison MD The Nevada Colon Cancer Partnership Objectives 1. Understand the incidence and mortality rates for CRC in the US. 2. Understand risk
More informationFinancial Disclosers
Slide 1 Colorectal Cancer Screening Jason Hemming, MD NESGNA November 15, 2014 Slide 2 Bio Slide 3 Financial Disclosers I have no actual or potential conflict of interest relation to this presentation
More informationColorectal Cancer Screening and Risk Assessment Workflow. Documentation Guide for Health Center NextGen Users
Colorectal Cancer Screening and Risk Assessment Workflow Documentation Guide for Health Center NextGen Users Colorectal Cancer Screening and Risk Assessment Workflow and Documentation Guide for Health
More informationCENTERS FOR DISEASE CONTROL AND PREVENTION CENTERS FOR DISEASE CONTROL AND PREVENTION. Incidence Male. Incidence Female.
A Call to Action: Prevention and Early Detection of Colorectal Cancer (CRC) 5 Key Messages Screening reduces mortality from CRC All persons aged 50 years and older should begin regular screening High-risk
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationWellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer
Wellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer Healthy Habits and Cancer Screening Rev 10.20.15 Page
More informationColonoscopy MM /01/2010. PPO; HMO; QUEST Integration 10/01/2017 Section: Surgery Place(s) of Service: Outpatient
Colonoscopy Policy Number: Original Effective Date: MM.12.003 12/01/2010 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration 10/01/2017 Section: Surgery Place(s) of Service: Outpatient
More informationQuality Measures In Colonoscopy: Why Should I Care?
Quality Measures In Colonoscopy: Why Should I Care? David Greenwald, MD, FASGE Professor of Clinical Medicine Albert Einstein College of Medicine Montefiore Medical Center Bronx, New York ACG/ASGE Best
More informationNeoplastic Colon Polyps. Joyce Au SUNY Downstate Grand Rounds, October 18, 2012
Neoplastic Colon Polyps Joyce Au SUNY Downstate Grand Rounds, October 18, 2012 CASE 55M with Hepatitis C, COPD (FEV1=45%), s/p vasectomy, knee surgery Meds: albuterol, flunisolide, mometasone, tiotropium
More informationColorectal Cancer Screening and Surveillance
Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0148 Colorectal Cancer Screening and Surveillance Table of Contents Related Coverage Resources
More informationClinical UM Guideline
Subject: Guideline #: Current Effective Date: 06/28/2016 Status: Revised Last Review Date: 05/05/2016 Description This document addresses colonoscopy, an endoscopic procedure which allows direct visual
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationThe New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?
The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? Robert A. Smith, PhD Cancer Control, Department of Prevention and Early Detection American Cancer Society
More informationColorectal Cancer Screening. Paul Berg MD
Colorectal Cancer Screening Paul Berg MD What is clinical integration? AMA Definition The means to facilitate the coordination of patient care across conditions, providers, settings, and time in order
More informationColorectal Cancer Screening Guideline Issue Brief Updated May 30 th, 2018
Colorectal Cancer Screening Guideline Issue Brief Updated May 30 th, 2018 Issue Summary The American Cancer Society has updated its colorectal screening guideline, which have been published in CA: A Journal
More informationGuidelines for Breast, Cervical and Colorectal Cancer Screening
Guidelines for Breast, Cervical and Colorectal Cancer Screening Your recommendation counts. Talk to your patients about screening for cancer. CancerCare Manitoba provides organized, population-based screening
More informationremoval of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2
Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance
More informationThis is the portion of the intestine which lies between the small intestine and the outlet (Anus).
THE COLON This is the portion of the intestine which lies between the small intestine and the outlet (Anus). 3 4 5 This part is responsible for formation of stool. The large intestine (colon- coloured
More informationJoint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies. Ashish Sangal, M.D.
Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies Ashish Sangal, M.D. Cancer Screening: Consensus & Controversies Ashish Sangal, MD Director,
More informationColorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed/Revised May 2018 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes
More informationACG Clinical Guideline: Colorectal Cancer Screening
ACG Clinical Guideline: Colorectal Cancer Screening Douglas K. Rex, MD, FACG 1, David A. Johnson, MD, FACG 2, Joseph C. Anderson, MD 3, Phillip S. Schoenfeld, MD, MSEd, MSc (Epi), FACG 4, Carol A. Burke,
More informationQuality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationEmerging Interventions in Endoscopy. Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital
Emerging Interventions in Endoscopy Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital Colon Cancer Colon cancer is common. 1 in 20 people in the UK will develop the disease 19 000
More informationPatologia sistematica V Gastroenterologia Prof. Stefano Fiorucci. Colon polyps. Colorectal cancer
Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Colon polyps Colorectal cancer Harrison s Principles of Internal Medicine 18 Ed. 2012 Colorectal cancer 70% Colorectal cancer CRC and colon
More informationLarry Hogan, Governor Boyd K. Rutherford, Lt. Governor Robert R. Neall, Secretary. CRF CPEST Program
Larry Hogan, Governor Boyd K. Rutherford, Lt. Governor Robert R. Neall, Secretary May 18, 2018 Maryland Cigarette Restitution Fund Cancer Prevention, Education, Screening and Treatment (CRF CPEST) Program
More informationWhen is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool
When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool Adenomas/Carcinoma Sequence Providing Time for Screening Normal 5-20 yrs 5-15 yrs
More informationIncreasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program
Increasing Colorectal Cancer Screening in Wyoming Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program Overview What is colorectal cancer? What are risk factors for
More informationColorectal Cancer Screening: A Clinical Update
11:05 11:45am Colorectal Cancer Screening: A Clinical Update SPEAKER Kevin A. Ghassemi, MD Presenter Disclosure Information The following relationships exist related to this presentation: Kevin A. Ghassemi,
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Colorectal Cancer Screening and Surveillance Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 19 References... 21 Effective
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationColorectal Cancer Screening
Scan for mobile link. Colorectal Cancer Screening What is colorectal cancer screening? Screening examinations are tests performed to identify disease in individuals who lack any signs or symptoms. The
More informationColorectal Cancer Screening. Dr Kishor Muniyappa 2626 Care Drive, Suite 101 Tallahassee, FL Ph:
Colorectal Cancer Screening Dr Kishor Muniyappa 2626 Care Drive, Suite 101 Tallahassee, FL 32308 Ph: 850-297-0351 What we ll be talking about How common is colorectal cancer? What is colorectal cancer?
More informationColorectal Cancer Screening
Recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer Colorectal Cancer Screening Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson
More informationSurveying the Colon; Polyps and Advances in Polypectomy
Surveying the Colon; Polyps and Advances in Polypectomy Educational Objectives Identify classifications of polyps Describe several types of polyps Verbalize rationale for polypectomy Identify risk factors
More information1101 First Colonial Road, Suite 300, Virginia Beach, VA Phone (757) Fax (757)
1101 First Colonial Road, Suite 300, Virginia Beach, VA 23454 www.vbgastro.com Phone (757) 481-4817 Fax (757) 481-7138 1150 Glen Mitchell Drive, Suite 208 Virginia Beach, VA 23456 www.vbgastro.com Phone
More informationImproving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)
Improving Outcomes in Colorectal Cancer: The Science of Screening Tennessee Primary Care Association October 23, 2014 Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancers Colorectal Cancer
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationOvercoming Barriers to Cancer Screening. Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancer American Cancer Society
Overcoming Barriers to Cancer Screening Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancer American Cancer Society Cancer Disparities Cancer Disparities: A Definition Cancer health disparities
More informationCologuard Screening for Colorectal Cancer
Pending Policies - Medicine Cologuard Screening for Colorectal Cancer Print Number: MED208.056 Effective Date: 08-15-2016 Coverage: I.Cologuard stool DNA testing may be considered medically necessary for
More informationLIST OF ABBREVIATIONS
Gastroenter oenterology 2005 Royal College of Physicians of Edinburgh Screening and surveillance for upper and lower gastrointestinal cancer JN Plevris Consultant Gastroenterologist and Honorary Senior
More informationColon Cancer Screening and Surveillance. Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011
Colon Cancer Screening and Surveillance Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011 Colorectal Cancer Preventable cancer Number 2 cancer killer in the USA Often curable if detected
More informationCRC Risk Factors. U.S. Adherence Rates Cancer Screening. Genetic Model of Colorectal Cancer. Epidemiology and Clinical Consequences of CRC
10:45 11:45 am Guide to Colorectal Cancer Screening SPEAKER Howard Manten M.D. Presenter Disclosure Information The following relationships exist related to this presentation: Howard Manten MD: No financial
More informationColorectal Cancer Screening What are my options?
069-Colorectal cancer (Rosen) 1/23/04 12:59 PM Page 69 What are my options? Wayne Rosen, MD, FRCSC As presented at the 37th Annual Mackid Symposium: Cancer Care in the Community (May 22, 2003) There are
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,
More informationColorectal Cancer Screening
Tool 2.1 Cancer Screening Basic Fact Sheet Are You at High Risk? Your risk for colorectal cancer may be higher than average if: stomach You or a close relative have had colorectal polyps or colorectal
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Virtual Colonoscopy / CT Colonography Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Virtual Colonoscopy / CT Colonography Professional Institutional
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY
More informationGENERAL COLORECTAL CANCER INFORMATION. What is colorectal cancer?
GENERAL COLORECTAL CANCER INFORMATION What is colorectal cancer? Colorectal cancer is cancer that develops in the colon or the rectum. The colon and rectum are parts of the digestive system, which is also
More informationDetection of Colorectal Neoplasms in Asymptomatic Patients
Detection of Colorectal Neoplasms in Asymptomatic Patients Scope This guideline provides recommendations for the detection of colorectal cancer and adenomas in asymptomatic patients. These recommendations
More informationNorthern Ireland Bowel Cancer Screening Programme. Pathways. Version 4 1 st October 2013
Northern Ireland Bowel Cancer Screening Programme Pathways These changes will be version controlled, led by the Quality Assurance Director for the Programme. Any updated versions will be circulated and
More informationCA Cancer J Clin 2006;56:
Guidelines for Colonoscopy Surveillance after Polypectomy: A Consensus Update by the US Multi- Society Task Force on Colorectal Cancer and the American Cancer Society *, Sidney J. Winawer, MD; Ann G. Zauber,
More informationGrand Rounds. Des Moines University. May 5, Durado Brooks, MD, MPH Director, Cancer Control Intervention American Cancer Society
Grand Rounds Des Moines University May 5, 2016 Durado Brooks, MD, MPH Director, Cancer Control Intervention American Cancer Society Case Summary Mrs. J is a 56 y o w female complaining of always tired;
More informationACTIVITY DISCLAIMER DISCLOSURE. Alvin B. Lin, MD, FAAFP. Audience Engagement System Step 1 Step 2 Step 3. Learning Objectives.
ACTIVITY DISCLAIMER Colorectal Cancer Alvin B. Lin, MD, FAAFP The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note
More information2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests)
Learning Objectives 1. Review principles of colon adenoma/cancer biology that permit successful prevention regimes 2. Describe pros/cons of screening interventions (including colonoscopy, CT colography,
More informationFECAL OCCULT BLOOD TEST
MEDICAL POLICY For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS FECAL OCCULT BLOOD TEST Policy Number: CMP - 023 Effective Date: January 1, 2018 Table
More informationLatest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population
Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics
More informationUpdates in Colorectal Cancer Screening & Prevention
Updates in Colorectal Cancer Screening & Prevention Swati G. Patel, MD MS Assistant Professor of Medicine Division of Gastroenterology & Hepatology Gastrointestinal Cancer Risk and Prevention Clinic University
More informationColorectal Cancer Early Detection, Diagnosis, and Staging
Colorectal Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can
More informationQuality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction
Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Efficiency DESCRIPTION:
More informationHow to Increase Preventive Screening Rates in Practice: An Action Plan for Implementing A Primary Care Clinician s Evidence-Based Toolbox and Guide
How to Increase Preventive Screening Rates in Practice: An Action Plan for Implementing A Primary Care Clinician s Evidence-Based Toolbox and Guide CRC Toolkit and Guide Available at http://www.cancer.org/aspx/pcmanual/pcm.swf
More informationColorectal Cancer: Screening & Surveillance
Objectives Colorectal Cancer: Screening & Surveillance Chanda K. Ho, MD MPH Advances in Internal Medicine Brief overview epidemiology and pathogenesis of colorectal cancer (CRC) To review screening modalities
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationGet tested for. Colorectal cancer. Doctors know how to prevent colon or rectal cancer- and you can, too. Take a look inside.
Get tested for Colorectal cancer Doctors know how to prevent colon or rectal cancer- and you can, too. Take a look inside. 1 If you re 50 or older, you need to get tested for colorectal cancer. It s one
More informationColorectal Cancer Screening
Colorectal Cancer Screening An Integrated Care Pathway of the Collaborative Care Network Subject Matter Expert: Kevin Wolov, DO Pathway Custodian: Pat Czapp, MD First, a Friendly Reminder... This Integrated
More informationColorectal Cancer Prevention Quantity and Quality Count
Colorectal Cancer Prevention Quantity and Quality Count Ernesto Drelichman, MD Gastrointestinal Surgery & Endoscopy Providence Hospital Key Messages Colorectal cancer can be prevented Screening reduces
More informationHow to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov R. Sáenz, FACG,FASGE
How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov 11 2017 R. Sáenz, FACG,FASGE Wheel has been discovered already Policy Planning Thanks to GBD Big Data CRC
More informationHow to effectively code for Endoscopic procedures in Gastroenterology
How to effectively code for Endoscopic procedures in Gastroenterology Ariwan Rakvit, MD Associate Professor Division of Gastroenterology Texas Tech University Health Science Center All rights reserved
More informationWellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 4: Colorectal Cancer Overview
Wellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 4: Colorectal Cancer Overview Cancer Types Rev. 10.20.15 Page 35 Colorectal Cancer Overview Group Discussion True False Not
More informationCancer Screenings and Early Diagnostics
Cancer Screenings and Early Diagnostics Ankur R. Parikh, D.O. Medical Director, Center for Advanced Individual Medicine Hematologist/Medical Oncologist Atlantic Regional Osteopathic Convention April 6
More informationAnalysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationChapter 7 Section 2.2. Clinical Preventive Services - TRICARE Prime
Medicine Chapter 7 Section 2.2 Issue Date: May 15, 1996 Authority: 32 CFR 199.17 1.0 POLICY 1.1 TRICARE Prime enrollees may receive Prime Clinical Preventive Services from any network provider without
More informationHOW TO EVALUATE ACTIVITIES INTENDED TO INCREASE AWARENESS AND USE OF COLORECTAL CANCER SCREENING. Using your toolkit to conduct an evaluation
EVALUATION TOOLKIT HOW TO EVALUATE ACTIVITIES INTENDED TO INCREASE AWARENESS AND USE OF COLORECTAL CANCER SCREENING Using your toolkit to conduct an evaluation Welcome Mary Doroshenk, MA Director National
More informationColon Cancer Screening. A Provider Opinion Survey
Colon Cancer Screening A Provider Opinion Survey 1. Background Information What is colon cancer? Who needs to be screened? Colorectal Cancer» Presence of abnormal cells in the colon or rectum that divide
More informationCancer Prevention and Early Detection Worksheet for Men
Page 1 of 5 Cancer Prevention and Early Detection Worksheet for Men While a tremendous amount of progress has been made in cancer research, we still don t understand exactly what causes most cancers. However,
More informationAlabama Breast and Cervical Cancer Early Detection Program (ABCCEDP) County Health Department Protocol
Alabama Breast and Cervical Cancer Early Detection Program (ABCCEDP) County Health Department Protocol BREAST AND CERVICAL CANCER TABLE OF CONTENTS ABCCEDP Overview and Purpose... 1 Clinical Guidelines...
More informationColorectal Cancer Screening in Later Life: Blum Center Rounds
Colorectal Cancer Screening in Later Life: Blum Center Rounds OCTOBER 10, 2018 Agenda CRC Screening and Surveillance Recommendation Screening for Colon Cancer later in life Discussion and listening Families
More informationCANCER SCREENING. Er Chaozer Department of General Medicine, Tan Tock Seng Hospital
CANCER SCREENING Er Chaozer Department of General Medicine, Tan Tock Seng Hospital Introduction Screening average risk patients Benefits and harms from screening Early cancer detection early treatment
More informationWhat is Colorectal Cancer?
COLORECTAL CANCER (CRC) What is Colorectal Cancer? Colorectal cancer (also known as colon cancer) is cancer of the colon and/or rectum and occurs when a growth in the lining of the colon or rectum becomes
More informationDysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background
SCENIC: Polypoid in UC Definition How do I practice for Surveillance of Colitis? Themos Dassopoulos, M.D. Director, BSW Center for IBD Themistocles.Dassopoulos@BSWHealth.org Tel: 469-800-7189 Cell: 314-686-2623
More informationColorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer
1016 CLINICAL GUIDELINES CME Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Douglas K. Rex, MD 1, C. R i chard B ol
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationColorectal Cancer Screening. Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital
Colorectal Cancer Screening Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital March, 2018 CRC Epidemiology 4th most common malignancy in US (136,000 cases/yr) 2nd
More informationMeasure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care
Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: The
More informationDiagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014
Diagnostics for the early detection and prevention of colon cancer Publication of DeeP-C Study Data in New England Journal of Medicine March 2014 Safe Harbor Statement Certain statements made in this presentation
More informationDavid P. Ryan, M.D. Clinical Director, MGH Cancer Center Chief, Hematology-Oncology, MGH
Colon Cancer 2015 David P. Ryan, M.D. Clinical Director, MGH Cancer Center Chief, Hematology-Oncology, MGH Colon Cancer Case presentation 72yo woman presented 1/03 abd discomfort and nausea Found to have
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationColorectal cancer screening: Is total prevention possible?
Just the facts colorectal cancer Colorectal cancer screening: Is total prevention possible? Jeffrey Fox, MD, MPH Concepts and Controversies 2011 2010 NCI estimates for US: 142, 570 new CRC diagnoses 51,370
More informationPage 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!
Cancer Screening!! Using Best Evidence to Guide Practice! Judith M.E. Walsh, MD, MPH! Division of General Internal Medicine! Womenʼs Health Center of Excellence University of California, San Francisco!
More information11/9/2015 OUTLINE. Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist
Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist Anil K Sharma MD FACP Professor of Clinical Medicine, University of Rochester Chief of Gastroenterology,
More information